Drug details:
Molecular formula: C₁₅H₁₇N₃O₂S

Standard name: 2-[(5-phenyl-1,3,4-oxadiazol-2-yl)sulfanyl]-1-piperidin-1-ylethanone

Synonyms:

2-[(5-phenyl-1,3,4-oxadiazol-2-yl)sulfanyl]-1-piperidin-1-ylethanone 2-[(5-phenyl-1,3,4-oxadiazol-2-yl)sulfanyl]-1-(piperidin-1-yl)ethanone 2-((5-phenyl-1,3,4-oxadiazol-2-yl)thio)-1-(piperidin-1-yl)ethanone 2-oxo-2-(1-piperidinyl)ethyl 5-phenyl-1,3,4-oxadiazol-2-yl sulfide 2-[(5-PHENYL-1,3,4-OXADIAZOL-2-YL)SULFANYL]-1-(PIPERIDIN-1-YL)ETHAN-1-ONE

Curated SMILES: C1CCN(CC1)C(=O)CSC2=NN=C(O2)C3=CC=CC=C3

Evidence for compound's anti-virulence activity:

Mycobacterium
Related VF: ESX-1 (ESAT-6 secretion system-1)
Target: Not determined
Drug effect: Activating ethionamide by inducing MymA expression and inhibiting ESX1-mediated secretion of virulence factors.
Max phase: Preclinical (in vitro)
Publication:
Gries R, et al., 2024. Discovery of dual-active ethionamide boosters inhibiting the Mycobacterium tuberculosis ESX-1 secretion system. Cell Chem Biol 31(4):699-711.e6.